Navigation Links
The Top 250 Developers of In-Vitro Diagnostics Tests for Cancer, Cardiovascular & Infectious Diseases
Date:3/16/2017

LONDON, March 16, 2017 /PRNewswire/ -- 

Did you know?

- Daniella Cramp is Global President, Cardiometabolic at Alere Inc..

- Beijing Wantai Biological Pharmacy's Beijing plant is the largest manufacturing base for the production of infectious diseases diagnostics in China.

- MDxHealth was the winner of the 2016 Frost & Sullivan Global Prostate Cancer Diagnostics Technology Innovation Award.

- iTP Biomedica Corp., the Canadian developer of diagnostic tools for cancers, is oriented to collaborative co-diagnostics development.

- Arbor Vita Corporation's flagship product - the OncoE6™ Cervical Test - has proven to be the most accurate test available worldwide for detecting cervical cancer. It is the only cervical cancer test that provides real-time results at the point-of-care.

- Response Biomedical Corp., a global leader in cardiovascular point-of-care testing, has a wide range of markers available on its RAMP® platform including Troponin I, CK-MB, Myoglobin, NT-proBNP and D-dimer.

- On May 25, 2016, Philips Handheld Diagnostics announced the launch of a new handheld blood test, the Minicare I-20 system, for rapid diagnosis (< 10 minutes) of a heart attack at the point-of-care.

- On February 1, 2017, Great Basin Scientific, Inc. announced the completion of the clinical trial and 510(k) submission to the FDA of its Bordetella Direct Test.

- Meridian Bioscience, Inc. reported full-year fiscal 2016 net revenues of $196.1 million.

- In July, 2016, the Swiss-based global biopharmaceutical group, Debiopharm Group™, acquired a majority holding in GenePOC, Inc., the Canadian developer of affordable, simple, and rapid point-of-care molecular diagnostic tests for infectious diseases.

These are just a tiny sample of the 1,000's of facts to be found in 'The Top 250 Developers Of In-Vitro Diagnostics Tests For Cancer, Cardiovascular & Infectious Diseases'.

This unique and comprehensive report (438 pages) identifies and profiles the leading 250 developers of in-vitro diagnostics tests for cancer, cardiovascular and infectious diseases. They are located right across the globe from the United States and Europe to India and China.

Report Target Market:

1) In-Vitro Diagnostics Companies

Usage: competitive/financial analysis and strategic partner/alliance identification.

2) Suppliers

'The Top 250 Developers Of In-Vitro Diagnostics Tests For Cancer, Cardiovascular & Infectious Diseases' is perfect for suppliers of raw materials, technology and services to identify top potential customers.

3) Distributors

This report is ideal for distributors of in-vitro diagnostics instruments and tests to identify the leading manufacturers with the best products.

4) Industry Associations:

'The Top 250 Developers Of In-Vitro Diagnostics Tests For Cancer, Cardiovascular & Infectious Diseases' is a useful reference tool for in-vitro diagnostic associations.

Note: Most people will be aware of some of the major developers of in-vitro diagnostics tests for cancer, cardiovascular and infectious diseases such as Accugenomics, Inc., Agendia Inc., altona Diagnostics GmbH, Biocept, Inc., bioLytical Laboratories Inc., CardioDx, Inc., GeneNews Limited, HiberGene Diagnostics and OvaGene Oncology, Inc. but this major new report looks at all 250 of the top companies - companies like:

- GenMark Diagnostics, Inc. - Founded in 2010 and headquartered in Carlsbad, California, United States, GenMark Diagnostics, Inc. (NASDAQ: GNMK) is a leading provider of automated, multiplex molecular diagnostic testing systems that detect and measure DNA and RNA targets to diagnose disease and optimise patient treatment. Utilizing GenMark's proprietary eSensor® detection technology, GenMark's eSensor XT-8® system is designed to support a broad range of molecular diagnostic tests with a compact, easy-to-use workstation and self-contained, disposable test cartridges. In June, 2016, the Company achieved the CE Mark for its ePlex® sample-to-answer multiplex molecular diagnostics System and ePlex® Respiratory Pathogen (RP) Panel and on December 22, 2016, GenMark announced that it had submitted 510(k) applications to the FDA for its ePlex® sample-to-answer System and Respiratory Pathogen (RP) Panel. The Company has revenue of $U.S. 49.2 million and 233 employees. GenMark is led by Hany Massarany, President And Chief Executive Officer.

- Chembio Diagnostic Systems, Inc. - Headquartered in Medford, New York, United States, Chembio Diagnostic Systems, Inc. (Nasdaq: CEMI) develops, manufactures, licenses and markets point-of-care diagnostic tests and technology for the detection of infectious diseases. The Company's Dual Path Platform (DPP®) technology is providing it with a significant pipeline of business opportunities for the development and manufacture of new products. On January 10, 2017 Chembio Diagnostic Systems, Inc. announced that the Company had completed the acquisition of RVR Diagnostics Sdn Bhd (RVR), a Malaysian, privately-held manufacturer and distributor of point-of-care diagnostic tests for infectious diseases. Founded in 1985, Chembio Diagnostic Systems, Inc. had revenues of $U.S. 24.3 million in 2015. It currently has 166 employees and is led by John J. Sperzel, Chief Executive Officer.

- Biocartis Group NV - Headquartered in Mechelen, Belgium, Biocartis Group NV is an innovative commercial stage, molecular diagnostics company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. The Company's proprietary MDx Idylla™ platform is a fully automated, real time system which offers accurate, highly-reliable molecular information from any biological sample in virtually any setting. Idylla™ addresses the growing demand for personalized medicine by allowing fast and effective treatment selection and treatment progress monitoring. Biocartis Group NV is developing and marketing a rapidly expanding test menu addressing key unmet clinical needs in oncology and infectious diseases, the fastest and largest growing segments of the $U.S. 5.0 billion MDx market. The Company employs 300 people and has revenue of $U.S. 16.7 million. Biocartis Group NV has been listed on Euronext Brussels (BCART) since April 2015 and is led by Rudi Pauwels, Chief Executive Officer.

Report data field structure is as follows:

- Company Name
- Address
- Telephone
- Fax
- Email
- Website
- Year Established
- Number of Employees
- Key Executives
- Company Description
- Products
- Clinical Specialties
- Revenue ($U.S. million)
- Location Status
- Ownership
- Stock Exchange/Ticker Symbol
- Parent Company

Download the full report: https://www.reportbuyer.com/product/4770695/

About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers
http://www.reportbuyer.com

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: query@reportbuyer.com
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/the-top-250-developers-of-in-vitro-diagnostics-tests-for-cancer-cardiovascular--infectious-diseases-300425069.html


'/>"/>
SOURCE ReportBuyer
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Profiles of the Top 200 Developers of In-Vitro Diagnostics Tests for Cancer & Infectious Diseases 2017 - Research and Markets
2. Global Micro Guide Catheters Market to Reach US$242.0 Million by 2024: Growing Count of Vascular Disorders and Aneurysms Ring Alarm Bells for Developers, Notes TMR
3. Falcon Physician weighs in on usability at EHRA Summit: Providers and Software Developers Collaborate to Improve EHR Usability
4. The Top 60 Developers Of Medical & Surgical Simulation Products Worldwide
5. CareConnectors and VRI Use PatientGraph Platform to Develop Mobile Application Framework for Developers
6. Global Microfluidics Sales to Exceed US$ 11 Bn by 2026 End, In-vitro Diagnostics to Attract Highest Revenues
7. Worldwide Top 600 In-Vitro Diagnostics Companies 2017 - Research and Markets
8. Global In-Vitro Diagnostics (IVD) Market 2012 to 2022 - Research and Markets
9. In-vitro Toxicology Testing Market Worth $44.7 Billion by 2022: Grand View Research, Inc.
10. Asia-Pacific In-Vitro Fertilization Services Market - Opportunities and Forecasts, 2014 - 2020
11. Global In-Vitro Diagnostics Packaging Market 2016-2020 - Leading Vendors are Bio-Rad, Corning, Greiner Bio-One & Narang Medical
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/8/2019)... ... January 08, 2019 , ... University Hospitals Urology Institute ... of Excellence. The designation recognizes that Dr. Jaeger has achieved a high level ... exemplary care for men suffering from symptoms associated with benign prostatic hyperplasia (BPH). ...
(Date:1/8/2019)... Tenn. (PRWEB) , ... January 08, 2019 , ... ... the United States every 4 ½ minutes. We can change that alarming statistic,” ... non-profit Organization of Teratology Information Specialists (OTIS). MotherToBaby is joining with leading prenatal ...
(Date:1/7/2019)... (PRWEB) , ... January 07, 2019 , ... uBiome, the ... provides insights to help individuals understand how their gut microbes offer support in metabolizing ... role in how long the toxic byproducts of breakdown linger in your body. The ...
Breaking Medicine Technology:
(Date:1/20/2019)... JOSE, Calif. (PRWEB) , ... January 19, 2019 ... ... and management, Dr. Nakahira is responsible for ensuring the availability, quality and delivery ... activities of Utilization Management, Case Management, Quality Improvement, Pharmacy, Long-Term Services and Supports ...
(Date:1/14/2019)... ... January 14, 2019 , ... After many months of ... new clinic in Phoenix, Arcadia Allergy & Asthma. This new allergy and asthma clinic ... it a great one stop destination for any immunological and respiratory medical care needs. ...
(Date:1/14/2019)... ... , ... Jeffery Nelson, M.D., FACS, FASCRS , Surgical ... Digestive Health & Liver Disease at Mercy Medical Center , now offers patients ... as a suction hemorrhoid ligator is used with the procedure; this device holds ...
(Date:1/14/2019)... Columbia (PRWEB) , ... January 14, 2019 , ... ... announce the availability of the newly updated International Audit Protocol Consortium (IAPC) EHS ... IAPC EHS audit protocols to understand the scope of their EHS regulatory obligations ...
(Date:1/11/2019)... BURLESON, Texas (PRWEB) , ... January 11, 2019 , ... ... will provide free dental services for low-income, underinsured individuals at its Burleson, TX ... exams and x-rays, fillings, cleanings and extractions . For ...
Breaking Medicine News(10 mins):